CURE Pharmaceutical (OTCQB: CURR) is a vertically integrated drug delivery and development company
Committed to improving drug efficacy, safety, and patient experience through its proprietary drug dosage
CURE Pharmaceutical [OTCQB: CURR] and Canopy Growth to Produce CBD Oral Thin Films
CURR has an FDA- and DEA- registered, GMP manufacturing facility and is a pioneering developer of CUREform™, a patented drug delivery platform. CUREform™ includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system.
CURR names Canopy Rivers Chairman John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors.
CURR offers combined technologies that provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURR partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector, with partnerships in the U.S.A, Canada, Israel, and other markets. The CURR company mission is to improve people’s lives by redefining how medicines are delivered and experienced.
CURR Products Fall Into Two Categories: Nutraceuticals (dietary supplements) and Pharmaceutical Medicines
Nutraceuticals:
CUREfilm® Sleep is a daily dietary supplement that delivers a unique blend of five active ingredients with the CUREfilm® platform to promote healthy sleep patterns. This product is launched in U.S. markets.
CUREfilm® D is a high-potency dietary supplement that provides 50,000 IU of Vitamin D3 delivered with the CUREfilm® platform.
CUREfilm™ Hemp delivers hemp extracts via the CUREfilm® dosage form. This product is launched in U.S. markets.
CUREfilm® β-Caryophyllene is a dietary supplement that contains 30mg of β-Caryophyllene, a powerful terpene known for its anti-inflammatory and analgesic properties.
Pharmaceuticals:
CUREfilm® Blue contains 50mg of Sildenafil delivered with the CUREfilm® platform.
CUREfilm® Canna delivers synthetic and plant-derived cannabinoids in an oral thin film for pharmaceutical indications.
CURR Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery
On February 5th CURR announced that it had signed an exclusive licensing agreement with ReLeaf Europe, one of Europe’s leading pharmaceutical groups specialized in medicinal cannabis products. The agreement grants ReLeaf Europe exclusive access to the CURR encapsulation technology for certain oral and topical cannabis products in the Netherlands, the world’s first medical cannabis market. ReLeaf Europe products will be the first to use the CUREinside™ quality mark to bolster consumer confidence. Europe is one of the world’s largest medical cannabis markets due to various governments’ approval for medicinal purposes.
ReLeaf Europe is one of the few pharmacy providers of pharmaceutical-grade medicinal cannabis oils in Europe and an ideal partner for the CURR first step into the European market because of its commitment to establishing clinical evidence and following EU GMP and GDP standards. Through this agreement, CURR will roll out its powered by CURE strategy that includes exclusive licensing relationships to build global market share.
ReLeaf Europe is tackling the largest market in the world for cannabis by establishing a foothold in Holland — a market estimated to reach $2.6B by 2028 — and by pursuing innovative delivery systems and distribution networks. CURR will power several ReLeaf Europe products, including one sublingual tincture and two topical creams to be launched in 2020.
Major Earnings Potential in the Emerging Medicinal Cannabis Industry
The Cannabis plant has an estimated 113 different compounds, out of which THC and CBD are the two main constituents. THC is mainly responsible for the psychoactive effects or the
feeling of “high” caused by the use of cannabis. CBD on the other hand, has several powerful anti-inflammatory, analgesic, neuroprotective and anti-anxiety properties, which explains its growing popularity to treat a plethora of medical conditions. Unlike THC, CBD does not have any psychotropic effects and hence is widely preferred.
CBD is now being used to treat a wide array of medical conditions such as cancer, cardiovascular anomalies, arthritis, anxiety, depression and Insomnia. In addition, it has also been proven to possess neuroprotective benefits that can treat diseases such as seizures, Multiple Sclerosis (MS), Alzheimer’s, Parkinson’s and Schizophrenia to name a few. There is a growing preference for CBD over traditional pharmaceutical options as these have minimal side effects and are non-addictive.
The global legal marijuana market is likely to reach over USD 66.3 billion by the end of 2025, as per a report by Grand View Research, Inc, growing at a CAGR of 23.9%. There is a growing acceptance of the curative effects of cannabis, with some countries such as Canada and certain states of U.S legalizing the use of Marijuana for medical and recreational use. Research has time and again shown that cannabinoids (CBD), extracted from the cannabis plant, have varied medical uses with minimal side effects, making it a sought-after alternative to traditional pharmaceutical options.
CURR has signed a licensing and collaboration agreement with
Vanguard Scientific Systems, Inc.
Vanguard is a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented cannabis extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers
The industry is poised to grow to $2.1 billion in 2020, a 700% increase from 2016. Those numbers are not only appealing to the players in the CBD market but also serve as an incredible opportunity the pharmaceutical companies to create novel solutions for disease with large unmet medical needs. CURR is strategically positioned with multiple high value assets and extremely well-placed marketing partners to optimize the company’s earnings potential in the growing fields of key drug supply and delivery solutions, including the multi-billion-dollar CBD marketplace. For more information on CURE Pharmaceutical (OTCQB: CURR) visit: www.curepharmaceutical.com.
DISCLAIMER:
Nothing in the contents transmitted on this board should be construed as an investment advisory, nor should it be used to make investment decisions. There is no express or implied solicitation to buy or sell securities. The author(s) may have positions in the stocks or financial relationships with the company or companies discussed and may trade in the stocks mentioned. Readers are advised to conduct their own due diligence prior to considering buying or selling any stock. All information should be considered for information purposes only. No stock exchange has approved or disapproved of the information here.